Gender-Affirming Child Abuse Prevention Act
- Bill Number
- H.R. 4953
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-08-12: Referred to the House Committee on the Judiciary.
- Last Updated
- 2025-09-19T14:45:27Z
AI-Generated Summary
Purpose of the Legislation
The bill, titled the "Gender-Affirming Child Abuse Prevention Act," aims to create a federal civil right of action (a legal way to sue in court) for individuals who received gender-related medical treatments while they were minors (under 18). It frames such treatments as potential harm and seeks to hold medical providers accountable through lawsuits.
Key Provisions
- Civil Right of Action:
- Individuals who received "gender-affirming care" (defined below) as minors can sue the person or entity that performed the treatment in a U.S. federal district court.
- Suits can be filed by the individual themselves (once they turn 18), or on their behalf by a legal guardian, family member, estate representative, or court-appointed person if the individual is under 18, mentally incompetent, incapacitated, or deceased.
- Jurisdiction requires a connection to interstate or foreign commerce, such as travel across state lines, use of interstate payment methods, communications, or tools involved in the treatment.
- Relief Available:
- Actual damages (real financial losses suffered) or liquidated damages of $250,000 per instance of treatment.
- Plus court costs, including reasonable attorney's fees.
- Definitions:
- Gender-Related Medical Treatment: Procedures or medications aimed at changing a person's physical characteristics to align with a perceived gender different from their biological sex. For females, this includes surgeries like hysterectomy or phalloplasty, testosterone doses, and puberty blockers (drugs that delay puberty). For males, it includes surgeries like vaginoplasty or breast augmentation, estrogen doses, and similar blockers. The Secretary of Health and Human Services can add other treatments.
- Exclusions: Does not apply to treatments for disorders of sex development (conditions where sex characteristics don't develop typically, confirmed by genetic or biochemical tests), ambiguous biological sex traits, or complications from prior such treatments.
- Sex: Biological status as male or female based on reproductive systems.
- Gender: Treated as a synonym for sex, explicitly excluding concepts like gender identity, expression, or roles.
- Male/Female: Defined by natural reproductive functions (sperm for males, eggs for females), allowing for rare developmental or genetic exceptions.
- Minor: Anyone under 18.
Significant Changes to Existing Law
- Introduces a new federal cause of action specifically for gender-related treatments on minors, which does not currently exist under U.S. law. Previously, such claims would rely on state tort laws (civil wrongs like medical malpractice) without a dedicated federal pathway or standardized damages.
- Establishes federal court jurisdiction by linking treatments to interstate commerce, potentially overriding state variations in laws on gender-affirming care.
- Provides fixed liquidated damages ($250,000 per treatment), a novel feature not common in general medical liability laws, making penalties more predictable and severe.
Potential Impacts
- On Citizens: Enables former minors (and their representatives) to seek financial compensation for treatments they view as harmful, potentially increasing lawsuits against providers. This could deter doctors and clinics from offering gender-affirming care to minors, affecting access for transgender youth and families.
- On Government Agencies: The Department of Health and Human Services gains a role in identifying additional treatments covered by the law, which may require new administrative processes or guidance.
- On International Relations: Minimal direct impact, though it could influence U.S. medical tourism or cross-border care involving minors if interstate/foreign commerce elements are invoked.
- Broader effects may include shifts in healthcare practices, with providers facing higher liability risks, and possible increases in legal costs for all involved.
Main Stakeholders Affected
- Individuals and Families: Minors who received or may receive gender-related treatments, their guardians, and families pursuing or defending lawsuits.
- Medical Providers: Doctors, surgeons, clinics, and hospitals performing such care, who could face direct liability and financial penalties.
- Healthcare Industry: Pharmaceutical companies producing puberty blockers or hormones, and insurers covering treatments, potentially facing indirect costs from litigation.
- Advocacy Groups: Organizations supporting transgender rights (who may oppose the bill as restrictive) and those focused on child protection (who may support it as safeguarding minors).
Notable Legal, Constitutional, or Political Implications
- Legal: Expands civil liability in healthcare, potentially leading to a surge in federal lawsuits and challenges to medical standards of care. The interstate commerce requirement invokes the Commerce Clause of the U.S. Constitution to establish federal authority, which could be tested in court.
- Constitutional: May raise questions about equal protection (treating gender-related care differently from other medical decisions) or parental rights (interfering with family medical choices). Definitions of sex and gender could conflict with evolving court interpretations of discrimination laws.
- Political: Highlights tensions between protecting minors from irreversible treatments and supporting gender-affirming healthcare access, likely sparking debates on bodily autonomy, medical ethics, and federal vs. state roles in health policy. As an introduced bill, its passage would signal a shift toward restricting such care nationwide.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Recent Actions
- 2025-08-12: Referred to the House Committee on the Judiciary.
- 2025-08-12: Introduced in House
- 2025-08-12: Introduced in House
Bill Versions
- Gender-Affirming Child Abuse Prevention Act — issued 2025-08-12 — PDF (10 pages)